My top ten tips for graduating fellows and faculty entering and continuing “early career” as I am transitioning into “mid-career”. A thread:

Evolutionary Role of GIP & GLP-1 Beyond Glycaemia https://t.co/R9EvOGw1hG @DrNadolsky @DrKarlNadolsky @drmatthewnagra @NutritionMadeS3 @MichaelAlbertMD @BevTchangMD

Imagine if everything in life was as good as gold. It’s easy to invest in, could help grow your wealth, and protect it too. A timeless asset that stands strong when others may not.

Calling all #FunctionNotFailure peeps 📢 Submit your ⭐️science in special populations: amyloid, sarcoidosis, myocarditis, & other infiltrative & inflammatory cardiomyopathies @JCardFail before December 8!!!! @robmentz @noshreza @AndrewJSauer @TomCascinoMD @heartofthemater

ANGPTL3 is a compelling target, for a few reasons 1. It's backed by a natural experiment: people with loss-of-function variants have lower LDL cholesterol and lower cardiovascular risk – with no clear negative effects 2. Its inhibition lowers not only LDL-C, but also

RCT demonstrating improved HF optimal therapy score and use of quadruple GDMT with a digital system Digital Platform to Optimize Guideline-Directed Heart Failure Therapy: Results of the AIM-POWER Trial | Circulation: HF https://t.co/GBTIUp8p1n @texhern @CircHF @biofourmis

Alien Roguelike Tower Defense Wishlist now: https://t.co/PP5J7dsTUp

Primary HF 🏨 in the US 2010 to 2022 Where is all the progress in preventing and treating HF??? Failure in discoveries? Failure in translation? Failure in implementation? https://t.co/IdAmM0d94y @JavedButler1 @HeartDocSadiya @DLBHATTMD @NMHheartdoc @robmentz @rblument1

Our latest analysis from the SHORE registry now in @TheJHLT comprised of nearly 2000 pts with heart transplant Read here about the risk of dual + GEP/dd-cfDNA https://t.co/p1sXtXIPBw @JeffTeuteberg @KiranKhush1 @CareDx

Everytime I get mad at my sports team for losing, I remind myself of what Giannis said. Arguably my favorite response to a reporter ever.

5 new articles out in HREV!🚀 • The future of atrial shunting in HF • Do all HF patients need admission? • Echo’s evolving role • Pharmacotherapy in cardio-oncology • Next-gen BNP/NT-proBNP biosensors Important questions! ( https://t.co/wcAycOBIky). @AndrewJSauer @AHajduczok

🖥️AI can play a key role in prevention, early detection & treatment of HF, driven by advancements like multimodal LLMs. But challenges like data privacy, system integration, clinician trust & fairness/bias need to be addressed. Learn more in this Review: https://t.co/cBUhh1cGap

In a primer out in Heart Failure Reviews, we ask a simple question that comes up every clinic day: “Do I really need to be admitted?” for acute decompensated HF. Led by Alexander Hajduczok and Nick Wettersten. We review why hospitalization has become the default for

@AndrewJSauer @AHajduczok @RyanTedfordMD @AndrewPAmbrosy @MichaelNassifMD @BrettSperryMD @noshreza @JeffTeuteberg @TomCascinoMD @DrMarthaGulati @hvanspall @AndrewJSauer Very pertinent question-Our 2 papers showing that telehealth-aided home-based management of acute decomp HF, can be a safe, effective alternative to hospitalisation and also save costs (£1100/patient episode) https://t.co/9oBZ2lxptw https://t.co/oYrrJoNhsA

Check out our new paper out in HF Reviews where we explore alternative pathways for treatment of acute decompensated HF, including emerging treatment strategies including intranasal bumetanide. @AndrewJSauer @UCSDCardiology @AndrewPAmbrosy

This might be the most badass brief report I’ve read in a long time. In @NEJM A team just published what feels like a glimpse straight into the future of cellular therapeutics: successful survival and function of transplanted allogeneic, CRISPR-edited beta cells with zero

Roger Federer broke the internet with one statistic that will change how you see every setback in your life. 1,526 singles matches. Won almost 80% of them. 20 Grand Slams. 103 titles. Now answer honestly: What percentage of total points do you think he won across his entire

In a primer out in Heart Failure Reviews, we ask a simple question that comes up every clinic day: “Do I really need to be admitted?” for acute decompensated HF. Led by Alexander Hajduczok and Nick Wettersten. We review why hospitalization has become the default for

Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary Trials In this participant-level pooled analysis of 4 large-scale HFpEF outcome trials, obesity and excess abdominal adiposity were highly

Prognosis After >50% Decline in eGFR in Heart Failure Patients: A Nationwide Real-World Study In this large real-world study, a >50% eGFR decline was associated with increased mortality and ESKD risk irrespective of diabetes status, underscoring its clinical relevance.

https://t.co/ufBLOXaKvl @AndrewJSauer great article about need for additional options in outpatient ADHF #enbumyst need more fire extinguishers not just alarms!!

Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock The LEVOECMO Randomized Clinical Trial   In patients with potentially reversible cardiogenic shock supported by VA-ECMO, levosimendan did not reduce the time to successful weaning from ECMO

Strengths and uncertainty on the evidence for #Vericiguat in #HFrEF and characteristics and outcomes of recent RCTs in #HeartFailure @ehj_ed @ESC_Journals @_antocannata